Skip to main content

Preparation, optimization and in vitro–in vivo evaluation of Shunxin sustained release granules



Shunxinzufang decoction is tutors, empirical formula and has been used in Chinese patients of HFpEF for several years. The aim of this study was to make into sustained release granules and select the best formula for the preparation of Shunxin sustained release granules and to evaluate its in vivo and in vitro drug release behavior.


Response surface methodology and Center composite design were applied to screen the optimal formula of Shunxin sustained release granules. HPLC was used to detect indicative ingredients—paeoniflorin, calycosin-7-glucoside and ferulic acid in Shunxin sustained release granules. The in vitro sustained release character of indicative ingredients was investigated in simulated digestive fluids. In-vivo process of active components was studied through pharmacokinetics.


The optimal formula of Shunxin sustained release granules consisted of 35% shunxinzufang extract and 65% HPMC/starch (HPMC/starch ratio = 2:1). Three indicative components can be separated well under selected HPLC conditions. Compared with Shunxinzufang extract, the active components of Shunxin sustained release granules have obvious sustained-release character and improved bioavailability.


Shunxin sustained release granules has obvious sustained-release character and improved bioavailability.


Heart failure with preserved ejection fraction (HFpEF) accounts for about 50% of patients with heart failure, and its only effective western medicine is diuretic [1]. Therefore, it is essential to find new therapeutics to overcome known chemicals’ disadvantages mentioned above or as prospective alternatives for the treatment of HFpEF. Generally, HFpEF patients requires long-term treatment of integrated traditional Chinese and western medicine.

In traditional Chinese medicine preparations, decoction is used to treat urgent diseases while pills or other solid dose forms are used to treat chronic diseases. Up to date, few of studies on sustained release preparations of Chinese medicine have been reported in Chinese or English periodicals. For example, Tongfeng granules, Yi-Shen granules, YuPing granules [2,3,4]. However, most of them are focusing on their pharmacodynamics, but few reported their formulation design, preparation and pharmacokinetics.

Shunxinzufang decoction consisted of twelve herbs: Salviae Miltiorrhizae Radix Et Rhizoma (Danshen), Radix ginsen Grubra (Hongshen), Astragali Radix (Huangqi), Radix Paeonia Rubra (Chishao), Chuanxiong Rhizoma (Chuanxiong), Poria (Fuling), Glycyrrhiza Radix Et Rhizoma (Gancao) et al., which has been used in Chinese patients of HFpEF for several years. Although the decoction shows satisfied efficacy in clinical practice, it is unstable, not suitable for long-term storage and inconvenient to transport. In order to provide a stable and portable Chinese materia medica preparation for courses of treatment to patients with HFpEF, the shunxinzufang decoction was made into sustained release granules. Beside the above-mentioned advantages, the sustained release granules can achieve sustained release and stable blood drug concentration, improved bioavailability and further improve clinical efficacy. Compared with decoction, solid granules can avoid bitter taste and then improve the compliance of patients.

In this study, high performance liquid chromatography (HPLC) method was applied to simultaneously determine three indicative ingredients which were thought as main active compounds of Shunxin sustained-release granules to the treatment of HFpEF. Response surface methodology and central composite design (CCD) were adopted to further optimize the formula of Shunxin granules. The in vitro drug release and in vivo pharmacokinetics in rabbits were respectively investigated for optimized formula to validate its sustained release property.


Instruments and reagents

LC-10 ATVP high performance liquid chromatography equipped with a C18 chromatographic column and SLD-10AVP UV detector (Shimadzu, Japan), DGG-9620A thermostatic blast oven (Shanghai, China), Re-52AA rotary evaporator (Shanghai, China).

Chinese materia medica were all provided by Baibao Pharmaceutical company (Gansu, China). They were authenticated by Dr. Jianying Li, School of Pharmacy Lanzhou University. Hydroxy-propyl methyl cellulose (HPMC) and pharmaceutical starch were supplied by Shanghai Yuanye Biological Technology Co., Ltd. (Shanghai, China). Standard samples of paeoniflorin and Ferulic acid were purchased from Shanghai Yuanye Biological Technology Co., Ltd. (Shanghai, China). Calycosin-7-glucoside was obtained from China’s Food and Drug Verification Research Institute (Beijing, China). Chromatographic grade methanol was purchased from Fisher Scientific (Shanghai, China). Chromatographic grade acetonitrile was purchased from MREDA Technology Inc. (Beijing, China). All other reagents were analytical grade.

Extraction of shunxinzufang extract and preliminary screening of excipient prescription

Preparation of shunxinzufang extracts and sustained release granules

Chinese materia medicas except Radix ginseng rubra are mixed together and firstly extracted with 8 times the volume of water for 2 h, then extracted with 4 times the amount of water twice and, each one took 1 h, respectively. Radix ginsen Grubra was singly extracted with 10 times the amount of water twice, and extracted with 8 times the amount of water for the third time. The water extracts are mixed together, filtrated and divided the Chinese materia medica solution equally. The filtrate was concentrated at 60 °C until the volume of extract sample was equivalent to the total quality of the tested Chinese materia medica. Then ethanol was added to the concentrated extract to precipitate polysaccharides. The resultant supernatant was transferred into a rotary evaporator to recover ethanol. Finally, the residue was evenly mixed with excipients, sifted through 16 mesh to make granules, dried at 60 °C, Shunxin granules was prepared.

Determination of the indicative ingredients of paeoniflorin, calycosin-7-glucoside and ferulic acid

The HPLC-system was equipped with a Diamonsil C18 (2) column (200 × 4.5 mm, 5 μm). The mobile phase consisted of acetonitrile and 0.1% phosphoric acid (17:83, v/v) with flow rate of 1.0 mL/min. The detection wavelength was set at 230 nm. The column temperature was 30 °C. The injection volume was 10 μL. A series of standard solutions of three indicative components including paeoniflorin, calycosin-7-glucoside and ferulic acid were made to construct standards curve. The receivable of the method was evaluated.

Preliminary screening of excipient

  1. (1)

    Filler screening

    Dextrin, lactose and starch are commonly used as fillers for Chinese materia medica granules. They are separately applied to make granules with matrix materials, and the optimal one was selected based on the granule formability, granule uniformity, fine powder rate and fluidity (angle of repose) as evaluation indexes.

  2. (2)

    Retardant screening

    Hydroxypropyl methyl cellulose (HPMC), sodium carboxymethyl cellulose (CMC-Na), microcrystalline cellulose (MCC), sodium alginate and carbopol were used as retardant for granulation. The evaluation indexes were the same mentioned above.

Single factor tests

When preparing a sustained-release preparation, hydrophilic but low solubility pharmaceutical materials are generally used, so starch was taken as filler, and HPMC as sustained-release material.

  1. (1)

    Extract content

    The mass ratio of HPMC and starch was fixed. Different amounts of extract were individually mixed with excipients to make granules. The granule formability, uniformity and fine powder rate were used as evaluation indexes. The extract content in the formula was screened out.

  2. (2)

    Ratio of HPMC and starch

    HPMC and starch mixed at a mass ratio of 1:1, 2:1, 3:1, 4:1 were used to make granules with fixed mass ratio of extract to excipient. The evaluation indexes were the same mentioned above.

In vitro release test

Dissolution test was performed using RC-8D Dissolution tester (Tianjin Xintianguang company, China). The 2 g sustained-release granules were added into 900 mL purified water at 37 ± 0.5 °C. The speed of rotation was set at 100 r/min. At different time intervals (2, 4, 6, 8, 10 and 12 h), 1 mL samples was withdrawn and quickly supplemented by fresh resolution medium. The withdrawn samples subsequently were filtered through a 0.45 μm organic filtration membrane. 20 μL of filtrates were injected into HPLC for analysis.

Central composite design experiment

A 2-factor, 5-level Central Composite design was used to optimize the Shunxin granule formula. According to the results of the single-factor tests, Shunxinzufang extract (%) (X1), HPMC/starch mass ratio (X2) were chosen as the main factors. The chosen dependent responses (Y1, Y2, Y3, Y4, Y5, Y6, Y7, Y8, Y9) were the cumulative release of Paeoniflorin, Calycosin-7-glucoside and Ferulic acid in 2 h, 6 h, 12 h. The independent variables (X1 and X2) and the responses in the experimental design were shown in Table 1. Experiments were automatically designed by Design Expert software (Version 8.0.6).

Table 1 Variables in central composite design experiments

Pharmacokinetic study

Animal experiment

Six male New Zealand rabbits were divided into two groups with a weight range of 2.0–2.5 kg. The use of animals was approved by Animal Ethics Committee of School of Basic Medical Sciences of Lanzhou University. The rabbits were Fasted for 12 h before the experiment, but access to drinking water freely. The experimental rabbits were given single dose of 4.4 g/kg of Shunxin sustained release granules and control rabbits were given single dose of 2 g/kg of Shunxinzufang extract by oral administration.

Blood samples (about 2 mL) were collected into heparinized polyethylene tubes from heart before and after administration at 0.25, 0.5, 1, 2, 4, 6, 8, 10, 12, 24 and 36 h, respectively. The blood samples were processed by centrifugation at 1900×g for 10 min. Then, the supernatant was decanted into polypropylene tubes and stored at − 80 °C until analysis.

Plasma sample preparation

The plasma was naturally thawed at room temperature. Each 1.0 mL plasma sample was pipetted in a 10 mL centrifuge tube. 2.0 mL chromatographic methanol and 1.0 mL hydrochloric acid were added into plasma sample. 20 μL of hesperidin (IS), 4 mL ethyl acetate: iso-propyl alcohol (v:v, 1:1) and 1 mL of blank plasma were added, and vortexed for 2 min. Then, the mixture was centrifuged at 13,000×g for 10 min. The supernatant was transferred into autosampler vials for HPLC analysis. The mobile phase consisted of acetonitrile (A) and 0.1% phosphoric acid aqueous (B) (0–10 min 17% A, 10–15 min 35% A, 15–20 min 50% A, 20–25 min 35% A, 25–30 min 17% A). Pharmacokinetic parameters were calculated using DAS 2.1 Pharmacokinetic Software Package (Mathematical Pharmacology Professional Committee of China, Shanghai, China).

Validation of analytical method

Selectivity was evaluated by comparing the chromatography of blank plasma sample, plasma sample spiked with paeoniflorin, calycosin-7-glucoside, ferulic acid and internal standard (hesperidin), plasma sample obtained from tested rabbits, and Shunxin sustained release granules. The linear regression equations of 3 major active ingredients were conducted by plotting the peak area ratio (Y) of the components to IS versus the concentration (X) of components, respectively. The intra-day and inter-day precision and accuracy were determined by analyzing quality control (QC) samples containing three concentrations (low, middle and high) of three standards on the same day and on different days. The precision and accuracy were evaluated by determining the 3 major active ingredients in QC samples at three different concentrations. Extraction recoveries of 3 major active ingredients were calculated by comparing the peak area of the extracted QC samples with those of unextracted standard solution containing the equivalent amount of 3 major active ingredients. Stabilities of 3 components were evaluated by QC samples kept at − 20 °C for 7 days and after three freeze/thaw cycles (− 20 °C to room temperature as one cycle).


In vitro HPLC analysis of three indicative components

Chromatographic peaks of paeoniflorin (1), calycosin-7-glucoside (2), and ferulic acid (3) can be well separated in shunxinzufang extracts (Fig. 1). The standard curve is drawn with the peak area as the ordinate (Y) and the mass concentration as the abscissa (X). The regression equations are Y = 12403x + 1555.6, (R2 = 0.9999), Y = 29700x + 449.7, (R2 = 1), Y = 31333x − 26,615, (R2 = 0.9999), indicating that paeoniflorin, calycosin-7-glucoside and ferulic acid have a good linear relationship. The average recoveries of paeoniflorin, calycosin-7-glucoside and ferulic acid were 98.3%, 90.5%, and 97.6%, respectively, and the RSD was 0.87%, 0.87%, and 0.50%, respectively. The details are listed in Additional file 1: Table S1.

Fig. 1

Chromatograms of the standard solution (a), the test solution (b); 1, 2, and 3 represent paeoniflorin, calycosin-7-glucoside and ferulic acid, respectively

Filler and retardant

  1. (1)


    It can be seen from Table 2 that the fine powder rate of dextrin filled granules was relatively higher compared with the other two fillers. After being wetted with water, it was of strong viscosity and was not easy to be sieved and granulated. Although lactose has good moisture resistance, poor moldability, but it is also expensive, and not suitable for large-scale use. The starch is cheap, biodegradable and biocompatible, and does not react with biologically active drugs. Which is the most commonly used pharmaceutical excipients. Taking these factors into account, starch was adopted to make granules.

  2. (2)


    Table 3 listed the screening results of the three matrix materials. During the granulation process, CMC-Na granules showed serious agglomeration, poor particle uniformity, and many fine powders. Both granules made with MCC and HPMC were satisfied, but MCC is relatively expensive. And considering the different pH of different parts of the gastrointestinal tract, HPMC, a non-pH dependent hydrogel material, was the ideal retardants. HPMC has good sustained-release ability for many different types of drugs, and is often used as a hydrophilic gel material for controlled release formulations [5]. A small amount of HPMC also has a certain viscosity when it is in contact with water, which is not conducive to sieve. However, starch can reduce the viscosity of HPMC. Therefore, the compatibility of starch and HPMC would result in a reasonable viscosity of mixture.

Table 2 Filler screening
Table 3 Matrix material screening

Single factor test

  1. (1)

    Extract ratio

    As can be seen from the Table 4, it is reasonable that the extract mass ratio accounted for 32–38% of the total formula. Therefore, in the subsequent experimental design, the extract content is selected from 32 to 38%.

  2. (2)

    HPMC and starch mass ratio

    It can be seen from Fig. 2 that when the mass ratio is 4:1, the three components cannot be completely released. At ratios of 1:1, 2:1, 3:1, the three components can be released relatively well.

    Fig. 2

    Cumulative release percentage

Table 4 Extract ratio screening

Central composite design statistical analysis

The Central Composite design results, using Design-Expert.v8.0.6. software to draw a three-dimensional effect surface map of the influence of various factors on the effect value (Fig. 3). Combining the three-dimensional effect surface map, using the Design-Expert.v8.0.6. software to predict the regression equation, the optimized formulation with the observed and predicted response values consisted of 35.06% shunxinzufang extract (X1) and 2.38:1 HPMC/starch ratio (X2). As expected, the result experimental values was in agreement with the values calculated from the models. Therefore, it can be concluded that response surface methodology is an effective method to optimize formulation of Shunxin sustained release granules. From Fig. 3, at 2 h and 6 h, X1 has no significant effect on the cumulative release rate of paeoniflorin, but slightly increased at 12 h. The cumulative release rate of paeoniflorin in X2 increased first and then decreased. At 2 h and 6 h, with the increase of X1, the cumulative release rate of calycosin-7-glucoside increased slightly, but was not significant at 12 h. X2 showed a trend of increased, decreased and then increased on the accumulation release rate of calycosin-7-glucoside. At 2 h and 6 h, X1 had no significant effect on the cumulation release rate of ferulic acid. At 12 h, it increased with the increase of X1. The cumulative release rate of ferulic acid by X2 increased first and then decreased. In summary, X2 significantly affected the cumulative release percentage of paeoniflorin, calycosin-7-glucoside and ferulic acid.

Fig. 3

Three-dimensional effect surface map. Y1, Y2 and Y3 represent cumulative release of paeoniflorin at 2 h, 6 h, 12 h (%) (a, b, c); Y4, Y5 and Y6 represent cumulative release of calycosin-7-glucoside at 2 h, 6 h, 12 h (%) (d, e, f); Y7, Y8 and Y9 represent cumulative release of ferulic acid at 2 h, 6 h, 12 h (%) (g, h, i)

The in vitro cumulative release rates of paeoniflorin, calycosin-7-glucoside and ferulic acid at 2 h, 6 h and 12 h were 17.58%, 52.05%, 89.15%; 14.28%, 48.05%, 84.15%; 29.43%, 46.93%, 62.65%, respectively, which indicated the mathematical model obtained by Design-Expert.v8.0.6. software was reliable and good for predictability. The details are listed in Additional file 1: Tables S2, S3, S4.

Pharmacokinetic analysis

Figure 4 shows the HPLC chromatograms of blank plasma (A), blank plasma spiked with IS (B), a plasma sample at 6 h after oral administration of Shunxinzufang extract (C) and a plasma sample at 10 h after oral administration of Shunxin sustained release granules (D). All target compounds were effectively separated. Typical equations for the calibration curves and correlation coefficients (R2) were as follows: Y = 0.1237x + 0.2419(R2 = 0.9993) for paeoniflorin, Y = 0.2621x + 0.209(R2 = 0.9983) for calycosin-7-glucoside, Y = 0.2381x − 0.7562(R2 = 0.9974) for ferulic acid. The calibration curves of the three analytes were linear in the ranges of 0.2–400 μg/mL for paeoniflorin, 0.1–200 μg/mL for calycosin-7-glucoside, 0.5–200 μg/mL for ferulic acid.

Fig. 4

Typical chromatograms of plasma samples. Chromatograms of blank plasma (a), blank plasma spiked with the analytes and IS (b), a plasma sample after oral administration of Shunxinzufang extract (c) and a plasma sample after oral administration of Shunxin sustained release granules (d). 1, 2, 3 and 4 represent paeoniflorin, calycosin-7-glucoside, ferulic acid and IS, respectively

The results of the precision, accuracy, extract recovery and stability at three concentration levels are summarized in Table 5. The plasma concentration–time curves of the three active components are shown in Fig. 5. Statistical analysis of the pharmacokinetic parameters (t1/2, Tmax, Cmax, AUC (0 − t), AUC (0 − ∞), MRT (0 − t), MRT (0 − ∞)) are shown in Table 6.

Table 5 The accuracy (intra- and inter-day) (n = 5), precision (n = 5), extract recovery (n = 5) and stability (n = 3) for 3 components in rabbits plasma
Table 6 Pharmacokinetic parameters
Fig. 5

Plasma concentration–time curves of the three compounds

From Fig. 5 and Table 6, we can know that the Shunxin sustained release granules have obvious sustain-release character compared with Shunxinzufang extract. Shunxinzufang extract is a liquid preparation, and its absorption is faster than that of the sustained-release granules, which is reflected in the peak time (6 h and 10 h respectively), indicating that the granules has sustained-release character. From Table 6, it can be seen that the biological half-life (t1/2) of Shunxin sustained release granules is significantly longer than Shunxin extract; the mean residence time [MRT (0 − t) and MRT (0 − ∞)] is significantly longer than the latter. These results confirmed that the sustained release granules have obvious release characteristics of paeoniflorin, calycosin-7-glucoside and ferulic acid. The area under the curve (AUC) of the sustained release granules was also significantly higher than the extract, demonstrating that the former preparation has higher bioavailability.


Chinese medicine has a reliable therapeutic effect on chronic heart failure, which can significantly improve the long-term prognosis of these patients and improve the quality of life. However, patients need to take long-term medication. Decoction is the main dosage form in the TCM clinical practice, but it is not stable, and not suitable for long-term storage. Thus Chinese materia medica needs to be freshly prepared and preserved for not more than 24 h, which reduces the compliance of patients with multi-courses treatment. The sustained and controlled release preparations can not only extend intervals between doses by slow release of active components, but also decrease possible systemic side-effect by maintaining relatively stable blood concentration after repeated medication. Shunxinzufang has been efficaciously used in patients of HFpEF. Among them, Astragali Radix has efficacies of tonifying qi and lifting yang, stopping perspiration with strengthening superficies, subsidening swelling and diuresis et al. Morden pharmacological research verified it has immune-stimulant, anti-bacterial, antiviral, hepatoprotective, anti-inflammatory, cardiovascular protection, and vasodilatory action [6,7,8,9]. Calycosin-7-glucoside, as the main component, has anti-oxidant, anti-inflammatory activities [10, 11]. RChuanxiong Rhizoma has the effect of promoting blood circulation, activating qi and relieving pain. It has antioxidant [12, 13], neuroprotection [14, 15], anti-inflammatory [16], anti-proliferative [17], anti-proliferation [18], and proapoptotic activities [19]. One of its main chemical constituent, ferulic acid, has anti-inflammatory, anti-oxidative and anti-tumor activity [20,21,22]. Radix Paeonia Rubra has effects of removing heat to cooling blood, promoting blood circulation to remove blood stasis. It has immuno-regulatory, anti-oxidant, antiallergic, and anti-inflammatory effects [23,24,25]. Paeoniflorin, the main compound isolated from its root, has anti-inflammatory, antioxidant, antidepressant and apoptotic effects [23, 26,27,28]. Taking the above-mentioned together, Shunxin sustained release granules have been designed and prepared, and its in vitro release property and in vivo pharmacokinetics with paeoniflorin, calycosin-7-glucoside and ferulic acid as the indicative components have also investigated.

HPMC has been reported showing an ideal function of extending drug release in drug delivery systems [29, 30]. Phaechawud et al. pointed that drug release was prominently sustained for over 12 h using HPMC-based hydrophilic matrix system [31]. Corn starch showed an increase in flowability with increasing moisture content, and the flowability of corn starch increased with moisture content until monolayer coverage was reached as the water provided increasing interparticle lubrication [32]. In this study, HPMC was used as the main sustained-release material and starch as the filling agent to complete the sustained-release characteristics of the particles. Response surface methodology and CCD were applied to screen the optimal formula of Shunxin sustained release granules. The optimal formula of Shunxin sustained release granules was 35% shunxinzufang extract and 65% HPMC/starch (HPMC/starch ratio = 2:1, w/w). When HPMC was used as the retardant material, it had a certain viscosity when exposed to water, while dried starch lack of strong viscosity. Therefore, starch was added in the granulation process to reduce the viscosity of HPMC. The details are listed in Additional file 1: Fig. S1.

In preliminary tests, it was found that the Shunxin sustained release granules can release about 62–90% marker components, which basically satisfy the requirement of sustained release preparations in China Pharmacopoiea [33]. Generally, sustained release preparations were administrated once daily or 2 times a day. After comprehensive consideration, we choose 12 h to take dissolution samples for analyses.

The cumulative release rate of paeoniflorin and calycosin-7-glucoside in 12 h were 89.15%, 84.15%, and ferulic acid was relatively low (62.65%). The release mechanism may be related to the characteristics of HPMC, mainly because of the three components in sustained release granules concentration difference inside and outside. And the concentration difference is used as the main driving force to release the paeoniflorin, calycosin-7-glucoside, and ferulic acid through the HPMC in granules surface formation of the gel layer and slow release. Three components have unreleased fully within 12 h, for the three components have not been completely released under the gel layer formed by HPMC. The results of pharmacokinetics showed that Shunxin sustained release granules had obvious sustained release characteristics and could significantly improve their bioavailability. The correlation coefficient squares (R2) between in vitro release and in vivo absorption for paeoniflorin, Calycosin-7-glucoside and ferulic acid were 0.9386, 0.9506 and 0.9431, respectively. These data showed the drug release in vitro and their absorption in rabbits contained good relativity, further proving that the optimized shunxin granules realized the purpose of this study.

Under the conditions of this formula, Shunxin sustained release granules demonstrated the advantages of stable quality, easy storage, convenient carrying and taking, etc. And it would create favorable conditions for improving medication compliance in patients with heart failure and further improving clinical efficacy. As adjuvant drugs, to combine with conventional chemical drugs, may be more effective for HFpEF. At present, there was not seen the application of sustained and controlled release preparations of Chinese materia medica on clinical practice in China. However, the whole controlled release of multi-components of Chinese materia medica is a major difficulty in the study of Chinese herbs sustained and controlled release preparations, and it is also the direction for further improvement of the preparation technology of this experiment.


Shunxin sustained release granules has obvious sustained-release character and improved bioavailability.

Availability of data and materials

All data are fully available without restriction.



heart failure with preserved ejection fraction


high performance liquid chromatography


hydroxypropyl methyl cellulose


sodium carboxymethyl cellulose


microcrystalline cellulose


quality control


  1. 1.

    Shah SJ, Cogswell R, Ryan JJ, Sharma K. How to develop and implement a specialized heart failure with preserved ejection fraction clinical program. Curr Cardiol Rep. 2016;18(12):122.

    Article  Google Scholar 

  2. 2.

    Mi Z, Yi-Fei W, Ru Z, et al. Treatment of gouty arthritis in different phases by a series of tongfeng granule: an efficacy observation. Chin J Integr Tradit West Med. 2013;33(12):1603–7.

    Google Scholar 

  3. 3.

    Jian-Sheng L, Su-Yun Y, Xue-Qing L, et al. Bu-Fei Yi-Shen granule combined with acupoint sticking therapy in patients with stable chronic obstructive pulmonary disease: a randomized, double-blind, double-dummy, active-controlled, 4-center study. J Ethnopharmacol. 2012;141(2):584–91.

    Article  Google Scholar 

  4. 4.

    Ma JF, Zheng JP, Zhong NS, et al. Effects of YuPingFeng granules on acute exacerbations of COPD: a randomized, placebo-controlled study. Int J Chronic Obstruct Pulman Dis. 2018;13:3017–24.

    Google Scholar 

  5. 5.

    Nikolakakis I, Partheniadis I. Self-emulsifying granules and pellets: composition and formation mechanisms for instant or controlled release. Pharmaceutics. 2017;9(4):E50.

    Article  Google Scholar 

  6. 6.

    Bedir E, Pugh N, Calis I, Pasco DS, Khan IA. Immunostimulatory effects of cycloartane-type triterpene glycosides from astragalus species. Biol Pharm Bull. 2000;23(7):834–7.

    CAS  Article  Google Scholar 

  7. 7.

    Pistelli L, Bertoli A, Lepori E, Morelli I, Panizzi L. Antimicrobial and antifungal activity of crude extracts and isolated saponins from Astragalus verrucosus. Fitoterapia. 2002;73(4):336–9.

    CAS  Article  Google Scholar 

  8. 8.

    Yusufoglu HS, Alam A, Zaghloul AM, Al-salkini MA, Alam P. Comparative anti-inflammatory and hepatoprotective activities of Astragalus gummifer Labill herb and roots in rats. Afr J Tradit Complement Altern Med. 2014;11(3):268–74.

    Article  Google Scholar 

  9. 9.

    Tao Y, Wang Y, Wang X, Wang C, Bao K, Ji L, et al. Calycosin suppresses epithelial derived initiative key factors and maintains epithelial barrier in allergic inflammation via TLR4 mediated NF-κB pathway. Cell Physiol Biochem. 2017;44:1106–19.

    CAS  Article  Google Scholar 

  10. 10.

    Yang Lei, Yang Changqing, Li Chenyi, Zhao Qing, Liu Ling, Fang Xin, et al. Recent advances in biosynthesis of bioactive compounds in traditional Chinese medicinal plants. Sci Bull (Beijing). 2016;61:3–17.

    Article  Google Scholar 

  11. 11.

    Li H, Wang P, Huang F, Jin J, Wu H, Zhang B, et al. Astragaloside IV protects blood-brain barrier integrity from LPS-induced disruption via activating Nrf2 antioxidant signaling pathway in mice. Toxicol Appl Pharmacol. 2018;340:58–66.

    CAS  Article  Google Scholar 

  12. 12.

    Ramalingam M, Yong-Ki P. Free radical scavenging activities of Cnidium officinale Makino and Ligusticum chuanxiong Hort. methanolic extracts. Pharmacogn Mag. 2010;6(24):323–30.

    CAS  Article  Google Scholar 

  13. 13.

    Jeong JB, Ju SY, Park JH, Lee JR, Yun KW, Kwon ST, et al. Antioxidant activity in essential oils of Cnidium officinale makino and Ligusticum chuanxiong Hort and their inhibitory effects on DNA damage and apoptosis induced by ultraviolet B in mammalian cell. Cancer Epidemiol. 2009;33(1):41–6.

    CAS  Article  Google Scholar 

  14. 14.

    Li J, Yu J, Ma H, Yang N, Li L, Zheng DD, et al. Intranasal pretreatment with Z-Ligustilide, the main volatile component of Rhizoma Chuanxiong, confers prophylaxis against cerebral ischemia via Nrf2 and HSP70 signaling pathways. J Agric Food Chem. 2017;65(8):1533–42.

    CAS  Article  Google Scholar 

  15. 15.

    Lin YL, Wang GJ, Huang CL, Lee YC, Liao WC, Lai WL, et al. Ligusticum chuanxiong as a potential neuroprotectant for preventing serum deprivation-induced apoptosis in rat pheochromocytoma cells: functional roles of mitogen-activated protein kinases. J Ethnopharmacol. 2009;122(3):417–23.

    Article  Google Scholar 

  16. 16.

    Or TC, Yang CL, Law AH, Li JC, Lau AS. Isolation and identification of anti-inflammatory constituents from Ligusticum chuanxiong and their underlying mechanisms of action on microglia. Neuropharmacology. 2011;60(6):823–31.

    CAS  Article  Google Scholar 

  17. 17.

    Li Y, Xu C, Zhang Q, Liu JY, Tan RX. In vitro anti-Helicobacter pylori action of 30 Chinese herbal medicines used to treat ulcer diseases. J Ethnopharmacol. 2005;98(3):329–33.

    Article  Google Scholar 

  18. 18.

    Lee TF, Lin YL, Huang YT. Studies on antiproliferative effects of phthalides from Ligusticum chuanxiong in hepatic stellate cells. Planta Med. 2007;73(6):527–34.

    CAS  Article  Google Scholar 

  19. 19.

    Chor SY, Hui AY, To KF, Chan KK, Go YY, Chan HL, et al. Anti-proliferative and pro-apoptotic effects of herbal medicine on hepatic stellate cell. J Ethnopharmacol. 2005;100(1–2):180–6.

    CAS  Article  Google Scholar 

  20. 20.

    Koh PO. Ferulic acid attenuates the down-regulation of MEK/ERK/p90RSK signaling pathway in focal cerebral ischemic injury. Neurosci Lett. 2015;588:18–23.

    CAS  Article  Google Scholar 

  21. 21.

    Cao YJ, Zhang YM, Qi JP, Liu R, Zhang H, He LC. Ferulic acid inhibits H2O2-induced oxidative stress and inflammation in rat vascular smooth muscle cells via inhibition of the NADPH oxidase and NF-κB pathway. Int Immunopharmacol. 2015;28(2):1018–25.

    CAS  Article  Google Scholar 

  22. 22.

    Wang JM, Sheng YC, Ji LL, Wang ZT. Ferulic acid prevents liver injury and increases the anti-tumor effect of diosbulbin B in vivo. J Zhejiang Univ Sci B. 2014;15(6):540–7.

    CAS  Article  Google Scholar 

  23. 23.

    Zhang MH, Feng L, Zhu MM, Gu JF, Wu C, Jia XB. Antioxidative and anti-inflammatory activities of paeoniflorin and oxypaeoniflora on AGEs-induced mesangial cell damage. Planta Med. 2013;79(14):1319–23.

    CAS  Article  Google Scholar 

  24. 24.

    Su J, Zhang P, Zhang JJ, Qi XM, Wu YG, Shen JJ. Effects of total glucosides of paeony on oxidative stress in the kidney from diabetic rats. Phytomedicine. 2010;17(3–4):254–60.

    CAS  Article  Google Scholar 

  25. 25.

    Tzeng Huey-En, Tsai Chun-Hao, Ho Tin-Yun, Ho Tin-Yun, Hsieh Chin-Tung, Chou Shen-Chieh, et al. Radix Paeoniae Rubra stimulates osteoclast differentiation by activation of the NF-κB and mitogen-activated protein kinase pathways. BMC Complement Altern Med. 2018;18(1):132.

    Article  Google Scholar 

  26. 26.

    Jianwei L, Shaohui H, Weiliang H, Wen G, Gao L, Fu X, et al. Paeoniflorin ameliorates interferon-alpha-induced neuroinflammation and depressive-like behaviors in mice. Oncotarget. 2017;8(5):8264–82.

    Google Scholar 

  27. 27.

    Huiming Hu, Zhu Qiaoqiao, Jie Su, Yajun Wu, Zhu Yanchen, Wang Yin, et al. Effects of an enriched extract of paeoniflorin, a monoterpene glycoside used in chinese herbal medicine, on cholesterol metabolism in a hyperlipidemic rat model. Med Sci Monit. 2017;23:3412–27.

    Article  Google Scholar 

  28. 28.

    Yong-Bin Z, Gao-Chun X, Shi-Lun T, Ding Y, Wang QS, Li SB, et al. Paeoniflorin inhibits human gastric carcinoma cell proliferation through up-regulation of microRNA-124 and suppression of PI3K/Akt and STAT3 signaling. World J Gastroenterol. 2015;21(23):7197–207.

    Article  Google Scholar 

  29. 29.

    Tao C, Chen J, Huang A, Zhang J, Lin B, Liu Z, et al. Development of solidified self-microemulsifying delivery systems with enhanced stability of sirolimus and extended release. Int J Pharm. 2016;513(1–2):255–61.

    CAS  Article  Google Scholar 

  30. 30.

    Zhang Y, Wang R, Wu J, Shen Q. Characterization and evaluation of self-microemulsifying sustained-release pellet formulation of puerarin for oral delivery. Int J Pharm. 2012;427(2):337–44.

    CAS  Article  Google Scholar 

  31. 31.

    Phaechamud T, Mueannoom W, Tuntarawongsa S, Chitrattha S. Preparation of coated valproic acid and sodium valproate sustained-release matrix tablets. Indian J Pharm Sci. 2010;72(2):173–83.

    CAS  Article  Google Scholar 

  32. 32.

    Crouter Allison, Briens Lauren. The effect of moisture on the flowability of pharmaceutical excipients. AAPS PharmSciTech. 2014;15(1):65–74.

    CAS  Article  Google Scholar 

  33. 33.

    State Pharmacopoeia Commission. Chinese pharmacopoeia, 2015 edition, the 4th volume. Beijing: China Medical Science and Technology Press; 2015.

    Google Scholar 

Download references


We thank Shilan Feng for her technical assistance.


This work was supported by Grants from Lanzhou science and technology planning project (2017-4-125), and Gansu administration of traditional Chinese medicine project (GZK-2016-15).

Author information




XFL designed the study. YHD conducted the experiment and wrote the manuscript. YBS guided the experiment. XYZ and JYZ helped carry out the experiment. YY, MRZ and WXX graphed pictures. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Xuefeng Li.

Ethics declarations

Ethics approval and consent to participate

Animals used in the current study were approved by Animal Ethics Committee of School of Basic Medical Sciences of Lanzhou University.

Consent for publication

All authors have provided consent for publication in the Journal of Chinese Medicine.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Dou, Y., Li, X., Shi, Y. et al. Preparation, optimization and in vitro–in vivo evaluation of Shunxin sustained release granules. Chin Med 14, 36 (2019).

Download citation


  • Shunxin sustained release granules
  • Formula optimization
  • Drug release
  • Pharmacokinetics